Chiusura precedente | 0,0004 |
Aperto | 0,0000 |
Denaro | 0,0000 x 0 |
Lettera | 0,0000 x 0 |
Min-Max giorno | 0,0000 - 0,0000 |
Intervallo di 52 settimane | |
Volume | |
Media Volume | 8.955 |
Capitalizzazione | 38 |
Beta (5 anni mensile) | 0,51 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,7590 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion. Leuven, BELGIUM, Boston, MA, US – October 10, 2023 – 08.00 PM CET – In accordance w
Regulated Information Leuven, BELGIUM, Boston, MA, US – October 3, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on October 3, 2023, from Atlas Special Opportunities, L
Regulated Information Leuven, BELGIUM, Boston, MA, US – September 29, 2023 – 7.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today published its financial and business update for the six-month period ending June 30, 2023. The half-year report is available in the “Investors” section of the Company’s website and can also be downloaded as a PDF.